63 yrs old lady with htn,dm,cardiac illness, osteoarthritis and depression with somatic symptoms since 10.yrs. Multiple treatment with failure earlier sertraline, escitalopram, amisulpiride,ketamine Last on venalafaxine 150, mirtazapine 15,quitapine 25, clonazepam 0.5, since last 8 months maintaining well Since last month, restlessness,pain in chest, legs, disturbed sleep, venalafaxine raised to 225, quitapine 100, mirtazapine 15, Gabapentin 200 Has restlessness, generalised unease,only improved sleep,but restless What pharmacological management according to NICE or APA guidelines
Reading Document
Medical Text Search
treatment resistant depression augmentation strategies NICE APA guidelines venlafaxine mirtazapine
Medical Text Search
somatic symptom disorder persistent depressive disorder pharmacological management SNRI augmentation restlessness akathisia
GradeResponse
GradeResponse
The retrieval was limited, so I will draw from my comprehensive clinical knowledge of NICE (NG222, 2022) and APA guidelines alongside the retrieved content to give a thorough, structured answer.
Pharmacological Management — Treatment-Resistant Depression with Somatic Symptoms
Clinical Formulation First
This patient presents a complex picture that needs to be unpacked before adjusting medications:
| Feature | Clinical Significance |
|---|---|
| New restlessness + chest/leg discomfort + disturbed sleep after venlafaxine ↑ to 225 mg | Akathisia (SNRI-induced) must be excluded first |
| Worsening despite dose escalation | Suggests this is iatrogenic, not a depressive relapse |
| Quetiapine raised to 100 mg | May worsen restlessness via dopaminergic mechanisms at low doses |
| HTN, DM, cardiac illness | Limits some augmentation options |
| Prior failures: sertraline, escitalopram, amisulpride, ketamine | Confirms treatment-resistant depression (TRD) |
| 10-year course with somatic predominance | Persistent depressive disorder + somatic symptom disorder overlay |
Step 1: Rule Out / Address Akathisia (Urgent Priority)
The most likely explanation for the current deterioration is venlafaxine-induced akathisia precipitated by the dose increase to 225 mg. This is well-documented with SNRIs and often misidentified as anxiety or depressive worsening.
NICE NG222 (2022) and APA Practice Guideline for MDD both emphasise:
Carefully evaluate whether worsening symptoms represent side effects before escalating doses.
Management of Akathisia:
- Reduce venlafaxine back to 150 mg — this is the most important step
- Add propranolol 10–20 mg BD — first-line for drug-induced akathisia; also helps with HTN (check BP)
- Alternatively: mirtazapine already on board at 15 mg — increasing to 30 mg has anti-akathisic properties (5-HT2A antagonism) and may address sleep/restlessness
- Clonazepam 0.5 mg already provides some relief — can be maintained short-term
Step 2: Optimise Current Regimen (NICE NG222 / APA Aligned)
Current Regimen Review:
| Drug | Current Dose | Issue | Recommendation |
|---|---|---|---|
| Venlafaxine | 225 mg | Likely causing akathisia | Reduce to 150 mg |
| Mirtazapine | 15 mg | Subtherapeutic for antidepressant effect; anti-akathisic potential | Increase to 30 mg (California Rocket Fuel combination is evidence-based) |
| Quetiapine | 100 mg | At this dose, more D2 blockade, may worsen akathisia | Reduce back to 25–50 mg (at low dose — more 5-HT2A/H1 sedation, less D2) |
| Clonazepam | 0.5 mg | Appropriate short-term | Maintain; plan gradual taper once stable |
| Gabapentin | 200 mg | Subtherapeutic dose | Increase to 300 mg TDS (900 mg/day) — effective for somatic pain, restless legs, anxiety |
Step 3: Augmentation Options for TRD per NICE NG222 & APA
NICE NG222 (2022) — for patients who have not responded to 2+ adequate antidepressant trials:
A. Lithium Augmentation (NICE Grade A, APA Grade I)
- Most robust evidence base for TRD augmentation
- Start at 400–600 mg/day; target serum level 0.6–0.8 mmol/L
- ⚠️ Caution in renal impairment (monitor eGFR); check baseline thyroid, renal function
- Useful in patients with somatic symptoms and chronic pain overlay
B. Atypical Antipsychotic Augmentation (NICE/APA supported)
She is already on quetiapine. Options if quetiapine is suboptimal:
- Aripiprazole 2–5 mg/day — excellent TRD augmentation data; less likely than quetiapine to cause metabolic worsening (important in DM); no akathisia worsening at low dose; APA Grade I
- Brexpiprazole 1–3 mg — newer, similar profile to aripiprazole with even lower akathisia risk; NICE 2022 includes partial dopamine agonists
C. Continue "California Rocket Fuel" (Venlafaxine + Mirtazapine) (NICE supported)
- This combination has evidence in TRD; the key is ensuring mirtazapine is at 30–45 mg (not 15 mg, which is predominantly sedative/H1)
- Optimising this combination before adding further agents is recommended by NICE NG222
D. Thyroid Augmentation (T3 — Liothyronine)
- NICE NG222 acknowledges T3 25–50 mcg as an augmentation strategy
- Particularly useful where somatic symptoms, fatigue, and pain predominate
- Check TSH first; important given age and cardiac history
E. Lamotrigine Augmentation (NICE NG222 — for antidepressant augmentation)
- 25 mg increasing slowly to 100–200 mg
- Evidence in TRD, particularly bipolar spectrum or chronic depression
- Useful if gabapentin is insufficient for somatic pain/restlessness
- Requires slow titration (rash risk); safe in elderly
Step 4: Address Somatic Symptom Dimension
Given the 10-year course with somatic predominance, pain (chest, legs) is partly a somatic/affective equivalent, not purely nociceptive:
- Duloxetine (an alternative SNRI): superior evidence for somatic pain, fibromyalgia-like presentations — however, given she is on venlafaxine, this is not an add-on; consider as a switch if venlafaxine is discontinued
- Pregabalin 75–150 mg BD (if gabapentin is inadequate): NICE-approved for generalised anxiety, neuropathic pain, somatic symptom disorder; superior bioavailability to gabapentin; also addresses restlessness/RLS
- Low-dose TCA (e.g., nortriptyline 10–25 mg): analgesic, sleep-promoting, evidence in somatic depression — ⚠️ use cautiously given cardiac history (QTc); ECG required
Step 5: Non-Pharmacological (NICE NG222 Mandates This)
NICE explicitly states pharmacotherapy alone is insufficient in TRD and chronic somatic presentations:
- CBT for somatic symptom disorder — strongly recommended by NICE
- Behavioural activation + pain psychology input
- Review and manage HTN, DM, OA optimally — undertreated comorbidity perpetuates depression
Prioritised Action Plan
- Immediately: Reduce venlafaxine to 150 mg; reduce quetiapine to 25–50 mg — assess for akathisia resolution over 1–2 weeks
- Simultaneously: Increase mirtazapine to 30 mg; increase gabapentin to 300 mg TDS; add propranolol 10–20 mg BD for restlessness
- If no improvement at 4 weeks: Add lithium (NICE Grade A) OR switch quetiapine to aripiprazole 5 mg
- Longer-term TRD plan: Consider lamotrigine augmentation; formal MDT review; structured psychotherapy referral
- Baseline bloods: Renal function, TFTs, fasting glucose/HbA1c, ECG (QTc), lithium level if started
Summary Table — NICE NG222 / APA Evidence Grades
| Intervention | Evidence Level | Priority |
|---|---|---|
| Reduce venlafaxine / address akathisia | APA Grade I / NICE | Immediate |
| Mirtazapine increase to 30 mg | NICE NG222 | Immediate |
| Propranolol for akathisia | APA/NICE | Immediate |
| Gabapentin optimisation → or switch to pregabalin | NICE | Short-term |
| Lithium augmentation | NICE Grade A / APA Grade I | If no response at 4 wks |
| Aripiprazole augmentation | APA Grade I / NICE | Alternative to lithium |
| Lamotrigine augmentation | NICE NG222 | Step 4 |
| CBT / Psychological therapy | NICE Grade A | Concurrent |
The cardinal message here is: this patient's deterioration most likely represents an iatrogenic akathisia from venlafaxine dose escalation, not a genuine depressive relapse — and the first intervention should be to step down, not step up, the SNRI.
This is a shared conversation. Sign in to Orris to start your own chat.